Griffiths C E
Department of Dermatology, University of Michigan Medical Center, Ann Arbor 48109-0314.
J Am Acad Dermatol. 1990 Dec;23(6 Pt 2):1242-6; discussion 1246-7. doi: 10.1016/0190-9622(90)70350-q.
Since 1984, cyclosporine has been used increasingly for indications other than in prophylaxis of transplant rejection. Current awareness that psoriasis is, at least in part, a T cell-mediated condition has led to the initiation of several studies of cyclosporine's role in the treatment of this disease. The remarkable efficacy of systemically administered cyclosporine, even in severely refractory cases of psoriasis, has not only provided us with a new therapeutic option but also has helped further our understanding of the pathophysiology of psoriasis. Although it has been hailed as a breakthrough, systemic cyclosporine usage is associated with undesirable sequelae, principally hypertension and decreased renal function. These effects limit its more widespread use. This review assesses current knowledge of the capabilities and prospects of systemic cyclosporine in the treatment of psoriasis, as well as the status of topical preparations.
自1984年以来，环孢素越来越多地被用于预防移植排斥反应以外的适应症。目前已知银屑病至少部分是一种由T细胞介导的疾病，这促使人们开展了多项关于环孢素在治疗该疾病中作用的研究。全身应用环孢素具有显著疗效，即使在严重难治性银屑病病例中也是如此，这不仅为我们提供了一种新的治疗选择，还有助于我们进一步了解银屑病的病理生理学。尽管全身应用环孢素被誉为一项突破，但它会带来不良后果，主要是高血压和肾功能下降。这些影响限制了其更广泛的应用。本综述评估了目前关于全身应用环孢素治疗银屑病的能力和前景的知识，以及局部制剂的现状。
